Fujisawa Pharmaceutical Co., Ltd. Chooses Sprint to Connect Operations in Asia, Europe and North America
Overland Park and TOKYO. Sprint announced that it has installed an IP VPN (Internet Protocol Virtual Private Network) for Fujisawa, a Japan-based pharmaceutical company with operations throughout Asia, Europe and North America.
Through a two-year agreement, Sprint will connect Fujisawa offices in Japan, China, Taiwan, Korea, Ireland, Germany, the United Kingdom, France, Switzerland, Netherlands, Sweden, Belgium, Italy, Spain and the United States.
"We wanted our network to mirror our corporate strategy, which aims to accelerate the speed of globalization," said Hiro Atsumaru, IT manager at Fujisawa. "With Sprint, we are able to increase nearly three to four times our network speed at no additional cost. We view this secure VPN solution as a critical tool to gain operational efficiency and grow our business."
"The global network development was the result of great collaboration among Fujisawa's Japan headquarters, Fujisawa's IT/IS departments in Germany and the United States as well as the Sprint network engineers," said Masahiko Sejima, director of IT Infrastructure Solution at Fujisawa System Technology Inc. "The plan was smoothly implemented because of the close and timely communication between all parties."
Sprint's IP VPN solutions can enable companies to communicate securely and cost effectively with employees, customers, business partners and suppliers. They provide the access required for establishing enterprise-wide intranets, extranets and remote access in addition to secure, encrypted connections necessary for transporting sensitive data across the Internet.
"Sprint's IP VPN solution, using Cisco Systems equipment, provides the security and flexibility that a global business like Fujisawa demands," said Kei Furuta, Sprint's managing director for Japan and Korea. "In addition, it's backed by Sprint's industry-leading service level agreements which provide businesses predictable, high levels of service across their networks."
Themen
Weitere News aus dem Ressort Wirtschaft & Finanzen

Holen Sie sich die Life-Science-Branche in Ihren Posteingang
Mit dem Absenden des Formulars willigen Sie ein, dass Ihnen die LUMITOS AG den oder die oben ausgewählten Newsletter per E-Mail zusendet. Ihre Daten werden nicht an Dritte weitergegeben. Die Speicherung und Verarbeitung Ihrer Daten durch die LUMITOS AG erfolgt auf Basis unserer Datenschutzerklärung. LUMITOS darf Sie zum Zwecke der Werbung oder der Markt- und Meinungsforschung per E-Mail kontaktieren. Ihre Einwilligung können Sie jederzeit ohne Angabe von Gründen gegenüber der LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin oder per E-Mail unter widerruf@lumitos.com mit Wirkung für die Zukunft widerrufen. Zudem ist in jeder E-Mail ein Link zur Abbestellung des entsprechenden Newsletters enthalten.